Novacyt Management

Management criteria checks 1/4

Novacyt's CEO is James McCarthy, appointed in Nov 2022, has a tenure of 1.5 years. total yearly compensation is £354.52K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.07% of the company’s shares, worth €41.28K. The average tenure of the management team and the board of directors is 1.5 years and 2.6 years respectively.

Key information

James McCarthy

Chief executive officer

UK£354.5k

Total compensation

CEO salary percentage	100.0%
CEO tenure	1.5yrs
CEO ownership	0.07%
Management average tenure	1.5yrs
Board average tenure	2.6yrs

Recent management updates

Recent updates

Little Excitement Around Novacyt S.A.'s (EPA:ALNOV) Earnings As Shares Take 25% Pounding

Sep 29

Novacyt's (EPA:ALNOV) Wonderful 999% Share Price Increase Shows How Capitalism Can Build Wealth

Mar 08

Is Novacyt S.A.'s(EPA:ALNOV) Recent Stock Performance Tethered To Its Strong Fundamentals?

Jan 22

Calculating The Intrinsic Value Of Novacyt S.A. (EPA:ALNOV)

Dec 15

We're Not Counting On Novacyt (EPA:ALNOV) To Sustain Its Statutory Profitability

Nov 19

CEO Compensation Analysis

How has James McCarthy's remuneration changed compared to Novacyt's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	n/a	n/a	-UK£25m
Mar 31 2023	n/a	n/a	-UK£24m
Dec 31 2022	UK£355k	UK£355k	-UK£22m
Sep 30 2022	n/a	n/a	-UK£11m
Jun 30 2022	n/a	n/a	UK£1m
Mar 31 2022	n/a	n/a	-UK£2m
Dec 31 2021	UK£512k	UK£74k	-UK£6m

Compensation vs Market: James's total compensation ($USD442.63K) is above average for companies of similar size in the French market ($USD324.51K).

Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.

CEO

James McCarthy (57 yo)

1.5yrs

Tenure

UK£354,517

Compensation

Mr. James Martin McCarthy had been Chief Financial Officer of Novacyt S.A. since January 5, 2021 until 2024, has been its Director since October 18, 2021 and serves as its Acting Chief Executive Officer si...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
James McCarthy	Acting CEO & Director	1.5yrs	UK£354.52k	0.070% £ 41.3k
Steve Gibson	CFO & Director	less than a year	no data	no data
Bryan Close	Chief Operations Officer	2.3yrs	no data	no data
Mandy Cowling	Corporate & Investor Relations Manager	no data	no data	no data
David Franks	Chief Human Resources Officer	3.1yrs	no data	no data
Paul Oladimeji	Group Head of R&D	no data	no data	no data
Lyn Rees	Executive Director	less than a year	no data	no data

1.5yrs

Average Tenure

Experienced Management: ALNOV's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
James McCarthy	Acting CEO & Director	2.6yrs	UK£354.52k	0.070% £ 41.3k
Steve Gibson	CFO & Director	less than a year	no data	no data
Lyn Rees	Executive Director	less than a year	no data	no data
John Brown	Non-Executive Director	less than a year	no data	no data
Andrew John Heath	Independent Senior Non-Executive Director	8.9yrs	UK£49.40k	0.028% £ 16.6k
Juliet Thompson	Independent Non-Executive Director	6.9yrs	UK£49.40k	no data
Jean-Pierre Crinelli	Independent Non-Executive Director	no data	UK£33.69k	0.048% £ 28.2k
David Gardner	Member of Scientific Committee	no data	no data	no data
Marco Zonta	Member of Scientific Committee	no data	no data	no data
Isabelle Cartier	Member of Scientific Committee	no data	no data	no data
Geneviève Bourg-Heckly	Member of Scientific Committee	no data	no data	no data
James Wakefield	Independent Non-Executive Chairman of the Board	10.3yrs	UK£128.33k	0.062% £ 36.4k

2.6yrs

Average Tenure

57yo

Average Age

Experienced Board: ALNOV's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Novacyt Management

Management criteria checks 1/4

Key information

Recent management updates

Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024

Novacyt S.A., Annual General Meeting, Jun 15, 2023

Novacyt S.A. Announces Retirement of Non-Executive Director, Effective on 31 December 2022

Novacyt Announces Step Down of David Allmond as Member of the Board

Novacyt S.A., Annual General Meeting, Jun 21, 2022

CEO & Director recently bought €121k worth of stock

Recent updates

Novacyt S.A. Notes DHSC Application for Summary Judgment Dismissed

New minor risk - Financial data availability

Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024

New minor risk - Share price stability

Is Novacyt (EPA:ALNOV) In A Good Position To Deliver On Growth Plans?

First half 2023 earnings released: UK£0.12 loss per share (vs UK£0.071 loss in 1H 2022)

New major risk - Revenue and earnings growth

Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023

Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023

We're Keeping An Eye On Novacyt's (EPA:ALNOV) Cash Burn Rate

Novacyt S.A., Annual General Meeting, Jun 15, 2023

Full year 2022 earnings released: UK£0.31 loss per share (vs UK£0.14 loss in FY 2021)

Now 23% undervalued after recent price drop

Novacyt S.A. to Report Fiscal Year 2022 Results on Apr 24, 2023

Estimating The Fair Value Of Novacyt S.A. (EPA:ALNOV)

Now 21% undervalued after recent price drop

Novacyt S.A. Announces Retirement of Non-Executive Director, Effective on 31 December 2022

Novacyt Announces Step Down of David Allmond as Member of the Board

Novacyt Announces Approval of genesig® SARS-CoV-2 Winterplex® 3 Gene Assay Panel in the UK Under CTDA Legislation

First half 2022 earnings released: UK£0.07 loss per share (vs UK£0.18 loss in 1H 2021)

Novacyt S.A. Provides Group Financial Guidance for the Third Quarter and Year-To-Date Ended September 2022 and Fourth Quarter of 2022

Novacyt S.A. to Report First Half, 2022 Results on Sep 29, 2022

Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-PCR Assays

Novacyt S.A. Launches Research-Use-Only Adenovirus F41 Assay

Novacyt S.A. Announces Approval of exsig COVID-19 Direct test in the UK

Novacyt Announces the Launch of Its Research-Use-Only Polymerase Chain Reaction Monkeypox Assay in Response to the Recent Outbreak of the Virus in Non-Endemic Countries

Novacyt S.A., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings released: UK£0.14 loss per share (vs UK£1.94 profit in FY 2020)

Novacyt S.A. Provides Update on DHSC Dispute

Novacyt Announces Approval of COVID-19 Test Under CTDA Legislation

CEO & Director recently bought €121k worth of stock

With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting

Novacyt S.A. Announces Approval of the First Direct-To-PCR Covid-19 Test in the UK Under CTDA Legislation

Novacyt S.A. to Report Fiscal Year 2021 Results on Apr 25, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting

Investor sentiment improved over the past week

High number of new directors

Investor sentiment improved over the past week

Little Excitement Around Novacyt S.A.'s (EPA:ALNOV) Earnings As Shares Take 25% Pounding

Investor sentiment improved over the past week

Novacyt S.A. Reiterate Revenue Guidance for the Full Year

Full year 2020 earnings released: EPS UK£1.94 (vs UK£0.072 loss in FY 2019)

Novacyt S.A. Provides Sales Guidance for the Full Year 2021

Novacyt S.A. Announces the Launch of Two New Polymerase Chain Reaction Assays, Expanding its genesig® COVID-19 and SNPsig® SARS-CoV-2 Variant Detection Portfolios

Novacyt S.A. Announces Launch of VersaLab™ Portable

Investor sentiment deteriorated over the past week

Price target decreased to €4.90

Novacyt S.A. Announces Inclusion of SNPsig SARS-CoV-2 PCR Genotyping Portfolio in the NHS England Framework and Expansion of SNPsig Product Range

Investor sentiment improved over the past week

Novacyt S.A. Provides Earnings Guidance for the Year 2021

Investor sentiment deteriorated over the past week

Novacyt's (EPA:ALNOV) Wonderful 999% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: €7.93

Investor sentiment deteriorated over the past week

Novacyt S.A. Announces Launch of PCR Genotyping Assay Portfolio to Detect Covid-19 Variants

New 90-day high: €13.24

Is Novacyt S.A.'s(EPA:ALNOV) Recent Stock Performance Tethered To Its Strong Fundamentals?

Investor sentiment improved over the past week

Novacyt S.A. Announces Board Changes

Novacyt S.A. Appoints James McCarthy as Chief Financial Officer

Calculating The Intrinsic Value Of Novacyt S.A. (EPA:ALNOV)

Novacyt S.A. Announces the Development of Three Tests for New Strains of COVID-19 and Avian Influenza

Market bids up stock over the past week

We're Not Counting On Novacyt (EPA:ALNOV) To Sustain Its Statutory Profitability

CEO & Director recently bought €558k worth of stock

Market pulls back on stock over the past week